This activity is expired and is no longer available for CME credit.


ROCK-solid Inhibition in Glaucoma Therapy

Author(s)/Faculty: John R. Samples, MD; Thomas W. Samuelson, MD; Janet B. Serle, MD
Release Date: 3/18/2019Expiration Date: 3/17/2020
Credit Type: CMENumber of Credits: 0
Content Type: LectureProvider:
The medical management of glaucoma is primarily focused on lessening intraocular pressure (IOP) by reducing aqueous humor formation or improving the drainage of aqueous humor via the uveoscleral pathway. Recent research has discovered novel classes of IOP-lowering drugs, such as rho kinase inhibitors, which expands current treatment options beyond the mainstays of prostaglandin analogs and β-blockers for the first time in more than two decades. Netarsudil is the first agent in the ROCK inhibitor class to be approved by the Food and Drug Administration for use in glaucoma and ocular hypertension. This CME activity will review the mechanisms of action of new and emerging IOP-lowering agents that target the rho-kinase pathway and evaluate evidence-based literature concerning the safety and efficacy of novel rho-kinase inhibitors in clinical practice.